

## Commissioning policy

<b>Treatment (brand name, manufacturer if applicable)</b>	Adalimumab (Humira, Abbott)
<b>For the treatment of</b>	Uveitis
<b>Background</b>	<p>Adalimumab is an inhibitor of tumour necrosis factor (TNF). It is given by subcutaneous injection.</p> <p>This treatment is excluded from PbR tariff.</p> <p>It is not licensed for the treatment of uveitis</p>
<b>Commissioning position</b>	<p>NHS Calderdale CCG will not routinely fund the use of Adalimumab in the treatment of uveitis</p> <p>No robust evidence of cost-effectiveness available so the PCT is not able to assure itself that this is a cost-effective use of resource</p>
<b>Effective from</b>	March 2011
<b>Summary of evidence/rationale</b>	There is no NICE/SMC guidance
<b>Date</b>	March 2011
<b>Policy to be reviewed by</b>	March 2013
<b>Contact for this policy</b>	Helen Foster – Medicines Management Lead <a href="mailto:Helen.Foster@calderdaleccg.nhs.uk">Helen.Foster@calderdaleccg.nhs.uk</a>